Delaware Court Advances Pfizer Vaccine Patent Case to Jury Trial, Rejecting Dismissal Bid

The chief judge of the Delaware federal court has declined a request from Pfizer and BioNTech to invalidate patent claims made against their COVID-19 vaccine, allowing the case to proceed to a jury trial later in the year. This development represents a significant moment in the ongoing legal disputes surrounding intellectual property rights and the COVID-19 vaccine, underscoring the complexities within pharmaceutical patent litigations. Details of the arguments and legal strategies from both sides have not been disclosed as the trial date approaches. Those interested in further details can read the original article available here.